ArticleVeterinary research2026
Host-parasite cross-species regulation by Schistosoma japonicum EV-miRNA sja-miR-2a-3p limits hepatic fibrosis via BCL2 suppression in hepatic stellate cells.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Schistosomiasis remains an important zoonotic parasitic disease, and hepatic fibrosis is a major cause of chronic pathology following Schistosoma japonicum infection. In schistosomiasis, hepatic fibrosis is the major cause of severe pathological damage. However, during the long-term co-evolution and coexistence between Schistosoma parasites and their hosts, the parasite can modulate the host hepatic fibrotic process through extracellular vesicle (EV)-mediated cross-species communication. In this study, we identified an EV-derived microRNA from Schistosoma japonicum, sja-miR-2a-3p, that suppresses hepatic pathology in the host. Using transwell co-culture and EV-isolation experiments, we confirmed that the helminth-specific sja-miR-2a-3p could be transferred to hepatic stellate cells (HSCs) via EVs. Bioinformatic and dual-luciferase assays revealed that host BCL2, a major anti-apoptotic gene, is a direct target of sja-miR-2a-3p. In vitro, sja-miR-2a-3p overexpression suppressed HSC proliferation and migration and induced mitochondrial dysfunction, caspase-3/-7/-9 activation, and apoptosis. In vivo, administration of sja-miR-2a-3p agomir to S. japonicum-infected mice significantly downregulated hepatic BCL2 expression, enhanced HSC apoptosis, alleviated granuloma formation, collagen deposition, and inflammation. Collectively, our findings reveal that schistosome EV-delivered sja-miR-2a-3p attenuates liver fibrosis by promoting mitochondrial apoptosis and functionally suppressing HSC activation. This study supports sja-miR-2a-3p as a candidate antifibrotic molecule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.